Clinical trials: Neoadjuvant Radiotherapy, open to volunteers
Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with…
- Trial name
- NCT07277842
- Testing
- Serplulimab, FOLFOXIRI chemotherapy, CAPOX chemotherapy
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1).
- Trial name
- TORCH-iTNT (NCT06281405)
- Testing
- PD-1 inhibitor, Capecitabine, Short-course radiotherapy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fudan University
Rectal Cancer
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
- Trial name
- NCT04643366
- Testing
- Chemotherapy, Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Virginia Commonwealth University
Lung Cancer (NSCLC), Neoadjuvant Immunotherapy
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
- Trial name
- NCT06926179
- Testing
- neoadjuvant immunotherapy
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Breast Cancer, Chemotherapy
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis…
- Conditions
- Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection
- Trial name
- ADARNAT (NCT04889924)
- Testing
- Axillary Radiotherapy, Lymphadenectomy
- Where
- 61 sites in Australia, Spain
- Volunteers
- 820 people
- Sponsor
- Hospital Universitari de Bellvitge
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer.
- Trial name
- NCT06130995
- Testing
- Relugolix and Enzalutamide
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Oklahoma
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the…
- Trial name
- NCT07700420
- Testing
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Rectal Cancer
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal…
- Trial name
- AMBITION (NCT05939661)
- Testing
- Radiation, Chemotherapy, Surgery
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Osaka University
Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST)
Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall
This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall.
- Conditions
- Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma of the Limb
- Trial name
- NEORASARC (NCT07507773)
- Testing
- Moderately hypofractionated neoadjuvant radiotherapy
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Centre Oscar Lambret
Rectal Adenocarcinoma
Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer
The PRELUDE Study: A Prospective Cohort Study Comparing Neoadjuvant Radiotherapy Followed by Total Mesorectal Excision Versus Upfront Surgery in Patients with Locally Advanced Proximal Rectal Cancer The PRELUDE Study is a…
- Trial name
- PRELUDE (NCT07802197)
- Testing
- radiotherapy, surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Radiotherapy can activate local and systemic immune responses through a variety of mechanisms, which can enhance anti-tumor immune effects.
- Trial name
- NCT06914050
- Testing
- Adebrelimab, EC/EP, SBRT
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical
Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC
Patients with stage III non-small-cell lung cancer (NSCLC) who receive neoadjuvant chemoimmunotherapy may achieve good response in the primary tumor but still have residual nodal disease after surgery (ypTanyN⁺M0), which is…
- Trial name
- NCT07353476
- Testing
- radiotherapy, PD -1/PD-L1 monoclonal antibody
- Volunteers
- 38 people
- Sponsor
- Shanghai Zhongshan Hospital
Invasive Breast Cancer
Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
RAPID-NeoBC is a prospective, multicentre, response-adapted study with a randomized component for adults with operable, nonmetastatic invasive breast cancer receiving guideline-recommended neoadjuvant systemic therapy.
- Trial name
- RAPID-NeoBC (NCT07892508)
- Testing
- Response-adapted preoperative radiotherapy, Guideline-recommended neoadjuvant systemic therapy, Serial contrast-enhanced breast MRI and breast-specific gamma imaging
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rectal Neoplasm
Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study
The introduction of neoadjuvant chemoradiation therapy (CRT) and the use of advanced surgical techniques have led to a reduction in mortality and recurrence rates for rectal cancer, the rate of which currently stands at 4-8%.
- Trial name
- RETRY (NCT05984576)
- Testing
- Reirradiation
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Locally Advanced Rectal Cancer (LARC)
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
In a single-center, prospective, phase II study (ClinicalTrials registration number: [to be filled in]) initiated by our center to evaluate the safety and preliminary efficacy of short-course radiotherapy followed by sequential…
- Trial name
- NCT07347951
- Testing
- Short-course radiotherapy, CAPOX chemotherapy, Targeted therapy with bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Adenocarcinoma of the Rectum
Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This study compares two standard radiotherapy approaches (short-course vs. long-course) given before surgery in patients with locally advanced rectal cancer.
- Trial name
- SHOOL (NCT07258797)
- Testing
- SCRT : 25 Gy in 5 fractions over 1 week to the pelvis using IGRT technique, LCRT + Consolidation Chemotherapy
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Rajiv Gandhi Cancer Institute & Research Center, India
Immunotherapy, Gastric Cancer (GC)
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Conditions
- Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
- Trial name
- NCT07165847
- Testing
- Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Thymic Carcinoma
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
The goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma.
- Trial name
- NCT07479628
- Testing
- adebrelimab plus chemoradiation
- Volunteers
- 31 people
- Sponsor
- Shanghai Chest Hospital